FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer

Article Link: FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer

TAIPEI, May 26, 2021 /PRNewswire/ — Foresee Pharmaceuticals (6576.TWO), (“Foresee”) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Camcevi 42 mg, a ready-to-use 6-month subcutaneous…

Source: FDA New Drug Approvals